BioRestorative Therapies, Inc. (BRTX)
1.46
-0.04
(-2.67%)
USD |
NASDAQ |
Oct 15, 16:00
1.43
-0.03
(-2.05%)
After-Hours: 20:00
BioRestorative Therapies Research and Development Expense (Quarterly) : 1.926M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.926M |
| December 31, 2025 | 2.627M |
| September 30, 2025 | 2.595M |
| June 30, 2025 | 2.226M |
| March 31, 2025 | 1.714M |
| December 31, 2024 | 1.658M |
| September 30, 2024 | 1.32M |
| June 30, 2024 | 1.292M |
| March 31, 2024 | 1.058M |
| December 31, 2023 | 0.6806M |
| September 30, 2023 | 0.8098M |
| June 30, 2023 | 0.9029M |
| March 31, 2023 | 1.232M |
| December 31, 2022 | 0.6736M |
| September 30, 2022 | 0.9892M |
| June 30, 2022 | 1.075M |
| March 31, 2022 | 0.7753M |
| December 31, 2021 | 0.1655M |
| September 30, 2021 | 0.2374M |
| June 30, 2021 | 0.1609M |
| March 31, 2021 | 0.1653M |
| December 31, 2020 | 0.1779M |
| September 30, 2020 | 0.251M |
| June 30, 2020 | 0.2616M |
| March 31, 2020 | 0.1863M |
| Date | Value |
|---|---|
| December 31, 2019 | 0.4158M |
| September 30, 2019 | 0.4098M |
| June 30, 2019 | 0.4417M |
| March 31, 2019 | 0.455M |
| December 31, 2018 | 0.3758M |
| September 30, 2018 | 0.3574M |
| June 30, 2018 | 0.3728M |
| March 31, 2018 | 0.4071M |
| December 31, 2017 | 0.2452M |
| September 30, 2017 | 0.4907M |
| June 30, 2017 | 0.6107M |
| March 31, 2017 | 0.8059M |
| December 31, 2016 | 0.7527M |
| September 30, 2016 | 0.6562M |
| June 30, 2016 | 0.6087M |
| March 31, 2016 | 0.866M |
| December 31, 2015 | 0.6301M |
| September 30, 2015 | 0.6156M |
| June 30, 2015 | 0.4525M |
| March 31, 2015 | 0.4069M |
| December 31, 2014 | 0.3528M |
| September 30, 2014 | 0.2907M |
| June 30, 2014 | 0.2933M |
| March 31, 2014 | 0.4937M |
| December 31, 2013 | 0.4058M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Myriad Genetics, Inc. | 25.00M |
| CareDx, Inc. | 22.38M |
| Natera, Inc. | 228.07M |
| Exagen, Inc. | 1.426M |
| Sera Prognostics, Inc. | 3.331M |